Cantor Fitzgerald Predicts Kura Oncology FY2025 Earnings

Kura Oncology, Inc. (NASDAQ:KURA - Free Report) - Equities researchers at Cantor Fitzgerald boosted their FY2025 earnings per share estimates for Kura Oncology in a research report issued on Wednesday, March 19th. Cantor Fitzgerald analyst L. Watsek now anticipates that the company will earn ($2.21) per share for the year, up from their previous forecast of ($2.94). Cantor Fitzgerald has a "Strong-Buy" rating on the stock. The consensus estimate for Kura Oncology's current full-year earnings is ($2.44) per share.

A number of other equities research analysts also recently commented on the company. BTIG Research downgraded Kura Oncology from a "buy" rating to a "neutral" rating in a report on Thursday, February 6th. Scotiabank lowered their target price on shares of Kura Oncology from $18.00 to $10.00 and set a "sector perform" rating for the company in a research note on Wednesday, January 8th. StockNews.com lowered shares of Kura Oncology from a "buy" rating to a "hold" rating in a report on Tuesday, March 18th. UBS Group decreased their price target on shares of Kura Oncology from $27.00 to $14.00 and set a "buy" rating for the company in a report on Thursday, March 6th. Finally, Wedbush restated an "outperform" rating and issued a $36.00 price objective on shares of Kura Oncology in a research report on Thursday, February 27th. Four equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $25.50.

Remove Ads

Kura Oncology Trading Down 6.9 %

NASDAQ KURA traded down $0.53 during trading hours on Friday, hitting $7.12. The company's stock had a trading volume of 653,973 shares, compared to its average volume of 1,062,298. The stock has a fifty day moving average of $7.83 and a 200 day moving average of $12.21. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. Kura Oncology has a twelve month low of $6.79 and a twelve month high of $23.48. The firm has a market capitalization of $574.98 million, a P/E ratio of -3.02 and a beta of 0.85.

Kura Oncology (NASDAQ:KURA - Get Free Report) last announced its earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share for the quarter, beating analysts' consensus estimates of ($0.65) by $0.43. The business had revenue of $53.88 million during the quarter, compared to analyst estimates of $57.96 million.

Institutional Investors Weigh In On Kura Oncology

A number of large investors have recently added to or reduced their stakes in KURA. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in Kura Oncology by 35.2% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 29,655 shares of the company's stock valued at $579,000 after acquiring an additional 7,722 shares during the period. Intech Investment Management LLC purchased a new stake in shares of Kura Oncology in the third quarter worth $298,000. Charles Schwab Investment Management Inc. increased its stake in Kura Oncology by 2.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 624,952 shares of the company's stock valued at $12,212,000 after purchasing an additional 14,106 shares in the last quarter. Algert Global LLC increased its holdings in shares of Kura Oncology by 4.4% in the 3rd quarter. Algert Global LLC now owns 272,276 shares of the company's stock worth $5,320,000 after purchasing an additional 11,493 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd purchased a new position in shares of Kura Oncology during the third quarter valued at approximately $596,000.

Insider Activity at Kura Oncology

In other news, SVP Thomas James Doyle sold 4,949 shares of Kura Oncology stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $38,948.63. Following the completion of the sale, the senior vice president now owns 88,193 shares in the company, valued at approximately $694,078.91. This trade represents a 5.31 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Mollie Leoni sold 4,963 shares of the firm's stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $39,058.81. Following the sale, the insider now owns 88,253 shares in the company, valued at approximately $694,551.11. This trade represents a 5.32 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 11,729 shares of company stock valued at $92,307. 5.50% of the stock is owned by insiders.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.